Literature DB >> 24342634

Validation of a novel murine wound model of Acinetobacter baumannii infection.

Mitchell G Thompson1, Chad C Black, Rebecca L Pavlicek, Cary L Honnold, Matthew C Wise, Yonas A Alamneh, Jay K Moon, Jennifer L Kessler, Yuanzheng Si, Robert Williams, Suleyman Yildirim, Benjamin C Kirkup, Romanza K Green, Eric R Hall, Thomas J Palys, Daniel V Zurawski.   

Abstract

Patients recovering from traumatic injuries or surgery often require weeks to months of hospitalization, increasing the risk for wound and surgical site infections caused by ESKAPE pathogens, which include A. baumannii (the ESKAPE pathogens are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). As new therapies are being developed to counter A. baumannii infections, animal models are also needed to evaluate potential treatments. Here, we present an excisional, murine wound model in which a diminutive inoculum of a clinically relevant, multidrug-resistant A. baumannii isolate can proliferate, form biofilms, and be effectively treated with antibiotics. The model requires a temporary, cyclophosphamide-induced neutropenia to establish an infection that can persist. A 6-mm-diameter, full-thickness wound was created in the skin overlying the thoracic spine, and after the wound bed was inoculated, it was covered with a dressing for 7 days. Uninoculated control wounds healed within 13 days, whereas infected, placebo-treated wounds remained unclosed beyond 21 days. Treated and untreated wounds were assessed with multiple quantitative and qualitative techniques that included gross pathology, weight loss and recovery, wound closure, bacterial burden, 16S rRNA community profiling, histopathology, peptide nucleic acid-fluorescence in situ hybridization, and scanning electron microscopy assessment of biofilms. The range of differences that we are able to identify with these measures in antibiotic- versus placebo-treated animals provides a clear window within which novel antimicrobial therapies can be assessed. The model can be used to evaluate antimicrobials for their ability to reduce specific pathogen loads in wounded tissues and clear biofilms. Ultimately, the mouse model approach allows for highly powered studies and serves as an initial multifaceted in vivo assessment prior to testing in larger animals.

Entities:  

Mesh:

Year:  2013        PMID: 24342634      PMCID: PMC3957858          DOI: 10.1128/AAC.01944-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Acinetobacter infection is associated with acquired glucose intolerance in burn patients.

Authors:  Dominic Furniss; Sinclair Gore; Berge Azadian; Simon R Myers
Journal:  J Burn Care Rehabil       Date:  2005 Sep-Oct

2.  Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.

Authors:  Katherine P Holloway; Nadine G Rouphael; Jane B Wells; Mark D King; Henry M Blumberg
Journal:  Ann Pharmacother       Date:  2006-10-03       Impact factor: 3.154

3.  A novel antibacterial gene transfer treatment for multidrug-resistant Acinetobacter baumannii-induced burn sepsis.

Authors:  Ravi Shankar; Li-Ke He; Andrea Szilagyi; Kuzhali Muthu; Richard L Gamelli; Marcin Filutowicz; Jennifer L Wendt; Hideki Suzuki; Miguel Dominguez
Journal:  J Burn Care Res       Date:  2007 Jan-Feb       Impact factor: 1.845

4.  Cutaneous wound healing is impaired in hemophilia B.

Authors:  Maureane Hoffman; Anna Harger; Angela Lenkowski; Ulla Hedner; Harold R Roberts; Dougald M Monroe
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

5.  The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections.

Authors:  Mircea Radu Mihu; Uriel Sandkovsky; George Han; Joel M Friedman; Joshua D Nosanchuk; Luis R Martinez
Journal:  Virulence       Date:  2010 Mar-Apr       Impact factor: 5.882

6.  Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.

Authors:  A Montero; J Ariza; X Corbella; A Doménech; C Cabellos; J Ayats; F Tubau; C Ardanuy; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  G Christopher Wood; Scott D Hanes; Bradley A Boucher; Martin A Croce; Timothy C Fabian
Journal:  Intensive Care Med       Date:  2003-10-11       Impact factor: 17.440

Review 8.  Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns.

Authors:  Lyudmila Boyanova; Ivan Mitov
Journal:  Expert Rev Anti Infect Ther       Date:  2013-04       Impact factor: 5.091

9.  A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.

Authors:  C R Gabaglia; B Pedersen; M Hitt; N Burdin; E E Sercarz; F L Graham; J Gauldie; T A Braciak
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

10.  Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases.

Authors:  Andres F Zuluaga; Beatriz E Salazar; Carlos A Rodriguez; Ana X Zapata; Maria Agudelo; Omar Vesga
Journal:  BMC Infect Dis       Date:  2006-03-17       Impact factor: 3.090

View more
  29 in total

Review 1.  Biofilms and Wounds: An Overview of the Evidence.

Authors:  Steven L Percival; Sara M McCarty; Benjamin Lipsky
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-07-01       Impact factor: 4.730

2.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor.

Authors:  Carolyn B Ibberson; Crystal L Jones; Shweta Singh; Matthew C Wise; Mark E Hart; Daniel V Zurawski; Alexander R Horswill
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

4.  Antimicrobial Blue Light Inactivation of Gram-Negative Pathogens in Biofilms: In Vitro and In Vivo Studies.

Authors:  Yucheng Wang; Ximing Wu; Jia Chen; Rehab Amin; Min Lu; Brijesh Bhayana; Jie Zhao; Clinton K Murray; Michael R Hamblin; David C Hooper; Tianhong Dai
Journal:  J Infect Dis       Date:  2016-02-17       Impact factor: 5.226

Review 5.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model.

Authors:  Gabriel J Pavey; Ammar T Qureshi; Donald N Hope; Rebecca L Pavlicek; Benjamin K Potter; Jonathan A Forsberg; Thomas A Davis
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

Review 7.  Options and Limitations in Clinical Investigation of Bacterial Biofilms.

Authors:  Maria Magana; Christina Sereti; Anastasios Ioannidis; Courtney A Mitchell; Anthony R Ball; Emmanouil Magiorkinis; Stylianos Chatzipanagiotou; Michael R Hamblin; Maria Hadjifrangiskou; George P Tegos
Journal:  Clin Microbiol Rev       Date:  2018-04-04       Impact factor: 26.132

Review 8.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

9.  Copper Resistance of the Emerging Pathogen Acinetobacter baumannii.

Authors:  Caitlin L Williams; Heather M Neu; Jeremy J Gilbreath; Sarah L J Michel; Daniel V Zurawski; D Scott Merrell
Journal:  Appl Environ Microbiol       Date:  2016-09-30       Impact factor: 4.792

10.  Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.

Authors:  Takashi Asahara; Akira Takahashi; Norikatsu Yuki; Rumi Kaji; Takuya Takahashi; Koji Nomoto
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.